No Data
Here's What To Make Of Shanghai Pharmaceuticals Holding's (SHSE:601607) Decelerating Rates Of Return
Sinolink: The end of year centralized purchasing expectations are gradually being cleared, and the pharmaceutical sector行情 is expected to gradually start.
The pharmaceutical Sector is currently in a process of a triple reversal in performance, policies, and funding, with full confidence in the recovery of revenue profit growth and market resurgence of listed companies in the Sector by 2025.
Shanghai Pharmaceuticals Gets Clinical Trial Approval for Varicose Vein Treatment
Shanghai Pharmaceuticals Gets US FDA Orphan Drug Designation for ALS Drug
SH PHARMA: SRD4610 has obtained orphan drug designation from the USA FDA.
On December 10, 2023, SH PHARMA (601607.SH) announced that its wholly-owned subsidiary, Shanghai Shangyao Ruir Pharmaceutical Co., Ltd., has independently developed SRD4610 for the treatment of amyotrophic lateral sclerosis (ALS) and received orphan drug designation from the USA Food and Drug Administration (referred to as "USA FDA"). SRD4610 is a compound Traditional Chinese Medicine Innovative Drug, and the project has completed a Phase II clinical trial for ALS in China.
Bearish landing? Hong Kong stocks in the pharmaceutical sector collectively strengthen with wuxi apptec rising over 8%.
① How much impact did the biological safety legislation have on domestic pharmaceutical stocks previously? ② How do industry insiders view the subsequent development of the biological legislation?
Return Trends At Shanghai Pharmaceuticals Holding (SHSE:601607) Aren't Appealing
